CHARLES MINARD to Pilot Projects
This is a "connection" page, showing publications CHARLES MINARD has written about Pilot Projects.
Connection Strength
0.377
-
Feasibility and acceptability of the TEAM pilot trial with African American and Latino families. J Pediatr Psychol. 2025 May 01; 50(5):388-398.
Score: 0.044
-
Development of an integrated milestone assessment tool across multiple early-adopter programs for breaking bad news: a pilot project. BMC Med Educ. 2024 Mar 20; 24(1):313.
Score: 0.041
-
Clinical application of home sleep apnea testing in children: a prospective pilot study. J Clin Sleep Med. 2022 Feb 01; 18(2):533-540.
Score: 0.035
-
Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. 2021 03; 11(3):e372.
Score: 0.033
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
Score: 0.032
-
Type 1 Doing Well: Pilot Feasibility and Acceptability Study of a Strengths-Based mHealth App for Parents of Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 2020 11; 22(11):835-845.
Score: 0.031
-
Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study. Acad Emerg Med. 2020 01; 27(1):54-60.
Score: 0.030
-
Featured Article: Strengths-Based, Clinic-Integrated Nonrandomized Pilot Intervention to Promote Type 1 Diabetes Adherence and Well-Being. J Pediatr Psychol. 2019 01 01; 44(1):5-15.
Score: 0.028
-
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer. 2018 12 01; 124(23):4548-4555.
Score: 0.028
-
Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders. Pediatr Blood Cancer. 2018 Jan; 65(1).
Score: 0.026
-
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
Score: 0.025
-
Physiologic and Acoustic Effects of Opera Performance. J Voice. 2017 Jan; 31(1):117.e11-117.e16.
Score: 0.024